Immuneoncia Therapeutics develops immunotherapies that utilize the body's immune system to target and eliminate cancer cells. The company focuses on creating effective treatments to reduce patient suffering from various types of cancer.
Funding
$60.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer remains a leading cause of death, and many patients do not respond to existing treatments. There is a need for novel therapeutic approaches that can effectively target and eliminate cancer cells while minimizing harm to healthy tissues.
Solution
Immuneoncia Therapeutics is developing a new generation of immunotherapies designed to harness the body's own immune system to fight cancer. Their approach focuses on identifying and targeting specific immune checkpoints that tumors exploit to evade immune detection and destruction. By blocking these checkpoints, Immuneoncia's therapies aim to reactivate anti-tumor immune responses, leading to durable remissions and improved patient outcomes. The company is committed to advancing innovative research and development to address unmet needs in cancer treatment.
Target Audience
The primary target audience includes cancer patients who are not responding to current treatments, as well as oncologists and researchers seeking new and more effective therapeutic options.
Features
- Focus on immune checkpoint inhibitors to enhance anti-tumor immunity
- Development of novel therapeutic antibodies targeting key immune regulatory pathways
- Preclinical and clinical studies to evaluate the safety and efficacy of immunotherapy candidates
- Proprietary technology platform for the discovery and development of innovative immunotherapies